Ireland
--:--IST
Recruiting Phase 1

Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain

NCT07122453 · tracked via the Priya Life Science USA tracker
Sponsor
Centrexion Therapeutics
Phase
Phase 1
Started
2026-03
Last updated
2026-03-23

Condition(s) studied

Lower Back Pain

Investigational drug(s) / intervention(s)

CNTX-3001Placebo

CNTX-3001: non-opioid analgesic

Placebo: Placebo product

Study summary

This clinical study is being conducted to evaluate the safety, tolerability, plasma pharmacokinetics and efficacy of an investigational drug called CNTX-3001. This Phase 1 study is the first time that CNTX-3001 will be given to people (first-in-human study). The study is being done to evaluate whether CNTX-3001, given into the intrathecal space by lumbar puncture, can be administered safely to participants who have been diagnosed with intractable chronic moderate to severe low back pain and who have not responded well to other treatments in the past.

CNTX-3001 is a novel, non-opioid small molecule

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion: * Have stable intractable, chronic moderate to severe low back pain * Must have failed all 3 of the following categories of therapies: 1. Physical medicine modalities for at least 6 weeks (e.g., physical therapy, occupational therapy, or chiropractic treatment directed at chronic low back pain) 2. Three or more classes of pharmacologic treatments 3. One or more non-surgical and/or surgical interventions addressing the primary cause of chronic low back pain * If the intractable low back pain is accompanied by radicular pain, back pain must be dominant over leg pain and may not radiate below the knee * Has normal leg strength in both legs (able to stand/walk) * Willing and able to undergo the lumbar puncture * On a stable analgesic regimen, or a stable dose of an opioid medication for \>3 months * Non- or ex-smoker and has not used any nicotine-containing products within 3 months * Men or women able to abide by reproductive and contraceptive requirements * Has a body mass index (BMI) between 18 and 35 kg/m2, with weight ≥60 kg Exclusion * Substantial increase or decrease in pain over the prior 3 months. * Low back pain that only occurs with specific activities or body positions. * Has asthma or other severe respiratory disease requiring daily prescription medication * History of, or current cancer (except basal cell carcinoma), cardiac disease, immunological disorders, meningitis, or bleeding disorders * Confirmed diagnosis of fibromyalgia or myalgic encephalomyelitis Exclusion * Substantial increase or decrease in pain over the prior 3 months * Low back pain that only occurs with specific activities or body positions * Has asthma or other severe respiratory disease requiring daily prescription medication * History of, or current cancer (except basal cell carcinoma), cardiac disease, immunological disorders, meningitis, or bleeding disorders * Confirmed diagnosis of fibromyalgia or myalgic encephalomyelitis

Primary outcome measure(s)

  • Incidence of treatment emergent adverse events — From baseline to the end of treatment visit (Day 7)
    Number of participants with TEAEs, which includes laboratory test variables

Trial sites (1)

FacilityCityRegionStatus
Neurovations Napa California Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07122453 on ClinicalTrials.gov ↗ ← All trials in the USA